Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 415

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Mosely, Suzanne I.S., Prime, John E., Sainson, Richard C.A., Koopmann, Jens-Oliver, Wang, Dennis Y.Q., Greenawalt, Danielle M., Ahdesmaki, Miika J., Leyland, Rebecca, Mullins, Stefanie, Pacelli, Luciano, Marcus, Danielle, Anderton, Judith, Watkins, Amanda, Coates Ulrichsen, Jane, Brohawn, Philip, Higgs, Brandon W., McCourt, Matthew, Jones, Hazel, Harper, James A., Morrow, Michelle, Valge-Archer, Viia, Stewart, Ross, Dovedi, Simon J., Wilkinson, Robert W.·2017·Cancer Immunology Research

Abstract

Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models is not fully understood, impeding appropriate preclinical model selection for target validation, and ultimately hindering drug development. Across a panel of commonly used murine syngeneic tumor models, we showed variable responsiveness to immunotherapies. We used array comparative genomic hybridization, whole-exome sequencing, exon microarray analysis, and flow cytometry to extensively characterize these models, which revealed striking differences that may underlie these contrasting response profiles. We identified strong differential gene expression in immune-related pathways and changes in immune cell–specific genes that suggested differences in tumor immune infiltrates between models. Further investigation using flow cytometry showed differences in both the composition and magnitude of the tumor immune infiltrates, identifying models that harbor “inflamed” and “non-inflamed” tumor immune infiltrate phenotypes. We also found that immunosuppressive cell types predominated in syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, whereas cytotoxic effector immune cells were enriched in responsive models. A cytotoxic cell–rich tumor immune infiltrate has been correlated with increased efficacy of immunotherapies in the clinic, and these differences could underlie the varying response profiles to immunotherapy between the syngeneic models. This characterization highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo. Cancer Immunol Res; 5(1); 29–41. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0114

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 415

Metadata

Authors
Mosely, S. I. S., Prime, J. E., Sainson, R. C. A., Koopmann, J.-O., Wang, D. Y. Q., Greenawalt, D. M., Ahdesmaki, M. J., Leyland, R., Mullins, S., Pacelli, L., Marcus, D., Anderton, J., Watkins, A., Coates Ulrichsen, J., Brohawn, P., Higgs, B. W., McCourt, M., Jones, H., Harper, J. A., Morrow, M., Valge-Archer, V., Stewart, R., Dovedi, S. J., & Wilkinson, R. W.
Venue
Cancer Immunology Research
Published
2017-01-01
Volume
5
Issue
1
Pages
29-41
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2560525946
Cited by
415
References
53
FWCI
11.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. https://app.cochat.ai/papers/10.1158/2326-6066.cir-16-0114
The paper
Mosely, S. I. S., Prime, J. E., Sainson, R. C. A., Koopmann, J.-O., Wang, D. Y. Q., Greenawalt, D. M., Ahdesmaki, M. J., Leyland, R., Mullins, S., Pacelli, L., Marcus, D., Anderton, J., Watkins, A., Coates Ulrichsen, J., Brohawn, P., Higgs, B. W., McCourt, M., Jones, H., Harper, J. A., . . . Wilkinson, R. W. (2017). Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-16-0114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.